A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Phase of Trial: Phase II
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Andecaliximab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 01 Mar 2017 This trial has been completed in Germany (end date: 2016-12-22).
- 13 Jan 2017 This trial has been completed in Spain (end date: 2016-12-22).
- 09 Jan 2017 Status changed from active, no longer recruiting to discontinued.